Luo M, Liu RN, He ZM, Liang QF, Huang FL. Diagnosis and treatment of metachronous multiple primary carcinoma: A case report and review of literature. World J Clin Oncol 2025; 16(5): 105444 [DOI: 10.5306/wjco.v16.i5.105444]
Corresponding Author of This Article
Feng-Ling Huang, Chief Physician, Department of Pharmacology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, No. 10 Huadong Road, Nanning 530000, Guangxi Zhuang Autonomous Region, China. 15676639131@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. May 24, 2025; 16(5): 105444 Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.105444
Diagnosis and treatment of metachronous multiple primary carcinoma: A case report and review of literature
Min Luo, Rui-Na Liu, Zhen-Mei He, Qian-Fu Liang, Feng-Ling Huang
Min Luo, Rui-Na Liu, Zhen-Mei He, Feng-Ling Huang, Department of Pharmacology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China
Qian-Fu Liang, Department of Radiotherapy, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530000, Guangxi Zhuang Autonomous Region, China
Co-first authors: Min Luo and Rui-Na Liu.
Author contributions: Liang QF designed the research and the treatment regimen; Luo M and He ZM analyzed the data and follow up with the patient and organize information; Liu RN and Huang FL performed the research; Luo M prepared the first draft of the manuscript and responsible for data re-analysis and re-interpretation; Liu RN responsible for figure plotting, comprehensive literature search, preparation and submission of the current version of the manuscript and thus qualified as the co-first authors of the paper; Huang FL have played important and indispensable roles in the experimental design, data interpretation and manuscript preparation as the corresponding authors; All authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng-Ling Huang, Chief Physician, Department of Pharmacology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, No. 10 Huadong Road, Nanning 530000, Guangxi Zhuang Autonomous Region, China. 15676639131@163.com
Received: January 23, 2025 Revised: February 27, 2025 Accepted: March 24, 2025 Published online: May 24, 2025 Processing time: 116 Days and 23.2 Hours
Core Tip
Core Tip: We report a case of a 40-year-old female diagnosed with invasive ductal carcinoma of the breast (T3N1M0 stage IIIA LuminalB type) as the first primary cancer and diffuse large B-cell lymphoma (DLBCL) (stage IIIA) as the second primary cancer. A modified radical mastectomy was selected for the treatment of left breast cancer and Rituximab, cyclophospha-mide, hydroxydaunorubicin, Oncovin (vincristine) and prednisolone regimen chemotherapy treatment to control DLBCL. At the last follow-up, the patient is in stable condition. In clinical practice, the simultaneous existence of metachronous primary breast cancer and lymphoma is rare. This case underscores the need for a multidisciplinary management approach and the adoption of advanced imaging techniques to facilitate early identification and treatment of rare multiple primary carcinoma cases.
